文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

药物相关高氨血症:基于WHO药物警戒数据库的贝叶斯分析

Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database.
PubMed 文献 · Ann Intensive Care · 2022-06-18
一句话结论基于VigiBase的贝叶斯不相称性分析识别出71种药物与高氨血症报告相关,其中60种此前未被认识,免疫抑制剂和肿瘤药物相关病例死亡率高。

该研究利用WHO药物警戒数据库VigiBase,采用信息成分(IC)进行不相称性贝叶斯分析,评估药物与高氨血症之间的关联。共识别出71种药物在2924例高氨血症病例中存在不相称报告,最常见药物为丙戊酸、氟尿嘧啶、托吡酯、奥沙利铂和门冬酰胺酶,另报告60种此前未被识别为高氨血症责任药物的品种,包括大麻二酚、巴利昔单抗、酪氨酸激酶抑制剂(舒尼替尼、索拉非尼、瑞戈非尼、仑伐替尼)及单克隆抗体(贝伐珠单抗、雷莫芦单抗)。病例严重程度随药物类别而异,接受免疫抑制剂和肿瘤药物的患者发生高氨血症时死亡率高。该研究为首次大规模药物相关高氨血症研究,可能有助于临床诊疗和试验设计。

要点

  • 在VigiBase中识别出71种药物与2924例高氨血症存在不相称报告,IC0.25>0视为有统计学意义。
  • 最常见涉及药物为丙戊酸、氟尿嘧啶、托吡酯、奥沙利铂和门冬酰胺酶。
  • 另报告60种此前未被识别为高氨血症责任药物的品种,包括大麻二酚、巴利昔单抗、舒尼替尼、索拉非尼、瑞戈非尼、仑伐替尼、贝伐珠单抗、雷莫芦单抗。
  • 接受免疫抑制剂和肿瘤药物且发生高氨血症的患者死亡率高。
  • 该研究为首次大规模药物相关高氨血症研究,可能有助于临床诊疗和试验设计。

适用人群与场景

  • 重症监护病房患者(高氨血症在此类患者中常见)
  • 使用肿瘤药物、抗癫痫药物、免疫抑制剂或精神科药物且发生高氨血症的患者

诊断标准与关键阈值

  • 采用信息成分(IC)进行不相称性贝叶斯分析,IC0.25(IC 95%可信区间下限)>0视为有统计学意义

研究设计与关键结果

  • 研究类型:基于VigiBase(WHO药物警戒数据库)的不相称性贝叶斯分析,使用信息成分(IC)比较观察值与预期值。
  • 共识别71种药物在2924例高氨血症病例中存在不相称报告。
  • 大多数可疑药物可归为4个主要治疗类别:肿瘤药物、抗癫痫药物、免疫抑制剂和精神科药物。
  • 最常涉及的药物为丙戊酸、氟尿嘧啶、托吡酯、奥沙利铂和门冬酰胺酶。
  • 另报告60种此前未被识别为高氨血症责任药物的品种,包括大麻二酚、巴利昔单抗、酪氨酸激酶抑制剂(舒尼替尼、索拉非尼、瑞戈非尼、仑伐替尼)和单克隆抗体(贝伐珠单抗、雷莫芦单抗)。
  • 病例严重程度随药物类别而异,接受免疫抑制剂和肿瘤药物且发生高氨血症的患者死亡率高。

证据类型、等级与局限

  • 证据类型:基于WHO药物警戒数据库VigiBase的不相称性贝叶斯分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究为首次大规模药物相关高氨血症研究,其描述可能有助于临床医生在患者诊疗中的决策以及试验设计(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hyperammonaemia is frequent in Intensive Care Unit patients. Some drugs have been described as associated with this condition, but there are no large-scale studies investigating this topic and most descriptions only consist of case-reports.

METHODS: We performed a disproportionality analysis using VigiBase, the World Health Organization Pharmacovigilance Database, using the information component (IC). The IC compares observed and expected values to find associations between drugs and hyperammonaemia using disproportionate Bayesian reporting. An IC0.25 (lower end of the IC 95% credibility interval) > 0 is considered statistically significant. The main demographic and clinical features, confounding factors, and severity of cases have been recorded.

RESULTS: We identified 71 drugs with a disproportionate reporting in 2924 cases of hyperammonaemia. Most of the suspected drugs could be categorised into 4 main therapeutic classes: oncologic drugs, anti-epileptic drugs, immunosuppressants and psychiatric drugs. The drugs most frequently involved were valproic acid, fluorouracil, topiramate, oxaliplatin and asparaginase. In addition to these molecules known to be responsible for hyperammonaemia, our study reported 60 drugs not previously identified as responsible for hyperammonaemia. These include recently marketed molecules including anti-epileptics such as cannabidiol, immunosuppressants such as basiliximab, and anti-angiogenics agents such as tyrosine kinase inhibitors (sunitinib, sorafenib, regorafenib, lenvatinib) and monoclonal antibodies (bevacizumab, ramucirumab). The severity of cases varies depending on the drug class involved and high mortality rates are present when hyperammonaemia occurs in patients receiving immunosuppressant and oncologic drugs.

CONCLUSIONS: This study constitutes the first large-scale study on drug-associated hyperammonaemia. This description may prove useful for clinicians in patients' care as well as for trial design.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Balcerac A, Bihan K, Lebrun-Vignes B, et al. Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database. Ann Intensive Care. 2022. PMID: 35716335. doi:10.1186/s13613-022-01026-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。